SAN DIEGO, Nov 5, 2015 – CareFusion, a BD company (NYSE:BDX), today announced its AirLife business line has signed an exclusive agreement with ResMed (NYSE:RMD) to distribute innovative nasal high flow interface products from the company.
“This agreement with ResMed is aligned with our commitment to providing the highest quality of respiratory products to our customers,” said Dan Woolson, president of Respiratory Technologies at BD. “This collaboration will help ensure our customers have access to a full portfolio of leading respiratory solutions.”
The agreement with ResMed includes exclusive distribution rights for its AcuCare™ high flow nasal cannula in the U.S. acute care market. ResMed’s nasal cannula offers a fast and intuitive fit, and is engineered to stay in place once fitted, providing speed and stability for built-in success in high flow oxygen therapy.
“The combination of ResMed products with AirLife’s reach will help provide more patients with innovative respiratory technology,” said Jim Hollingshead, president ResMed Americas. “This collaboration helps position ResMed for growth beyond what we could achieve alone.”
Additional terms of the agreements were not disclosed.
CareFusion, a BD company, serves the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops industry-leading technologies including Alaris® infusion pumps and IV sets, MaxPlus® and MaxZero™ IV connectors and sets, Pyxis® automated dispensing and patient identification systems, AVEA®, LTV® series and AirLife® ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. For more information please visit www.carefusion.com.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.
The global team at ResMed (NYSE:RMD) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit https://www.resmed.comor follow @resmed on Twitter.